SURMOUNT-MMO Long-Term Follow-Up: Where Tirzepatide Cardiovascular Outcomes Stand

Tirzepatide's cardiovascular outcome story has expanded meaningfully in 2026 as long-term SURMOUNT-MMO follow-up data has become available. Here's what the trial actually established, what it didn't, and where analysts are drawing lines.

The SURMOUNT-MMO Design

SURMOUNT-MMO enrolled adults with obesity or overweight plus established cardiovascular disease, randomized to tirzepatide or placebo, with major adverse cardiovascular events (MACE) as the primary composite endpoint. The trial powered specifically for a cardiovascular outcome — not just weight loss — putting it in the same category of importance as SELECT was for semaglutide.

The design mattered because tirzepatide's earlier weight-loss trials (SURMOUNT-1 through -4) established weight loss and metabolic improvement but didn't power for hard cardiovascular endpoints. SURMOUNT-MMO was the trial designed to answer that question directly.

What the Follow-Up Data Established

The long-term follow-up reinforced the primary readout: patients on tirzepatide experienced a statistically significant reduction in MACE compared to placebo. The magnitude was in the range clinicians expected given prior CV outcome trials for related agents. Cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke all trended in the favorable direction, with the composite hitting significance.

Secondary endpoints — heart failure hospitalizations, all-cause mortality — showed favorable trends without necessarily reaching individual statistical significance depending on the endpoint definition. This is a typical pattern for CV outcome trials, and analysts read the totality of evidence rather than individual endpoint p-values.

What the Data Didn't Establish

SURMOUNT-MMO doesn't establish that tirzepatide should be used primarily as a cardiovascular medication. It establishes that patients who need weight loss and have established CVD benefit from CV protection as a favorable secondary effect. Whether tirzepatide should be initiated for CVD alone — in patients without an obesity or overweight indication — remains an open clinical question.

The trial also doesn't establish direct comparative superiority over semaglutide for cardiovascular outcomes. That would require a head-to-head CV outcome trial, which no manufacturer has funded. Cross-trial comparisons of CVD reduction magnitude between SELECT and SURMOUNT-MMO are indirect and should be treated with appropriate caution.

How the Field Is Reading It

Practice pattern shifts have followed the data. Many clinicians who had used semaglutide as the default GLP-1 for patients with weight loss plus established CVD are now considering tirzepatide as an equally reasonable first-line choice on the basis of both metabolic magnitude and the emerging CV evidence. The magnitude of weight loss (which likely mediates much of the CV benefit) is larger with tirzepatide than semaglutide in head-to-head weight trials.

Insurance coverage decisions have started to reflect the new evidence, though slowly. Some payers have added tirzepatide with CVD indication to formularies where previously only diabetes indication was covered.

The Remaining Questions

What the field still wants to know: whether the CV benefit persists after discontinuation (relevant given real-world discontinuation rates); how the benefit distributes across primary vs secondary prevention populations; and whether the benefit magnitude differs meaningfully between patient subgroups (age, sex, baseline BMI, diabetes status). Ongoing follow-up and subgroup analyses over the coming years will answer these.

Where to Start